Chunghwa Chemical Synthesis & Biotech Co., Ltd.
TWSE:1762.TW
42.8 (TWD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,086.441 | 2,117.144 | 1,934.702 | 1,543.589 | 1,156.642 | 1,019.452 | 1,168.248 | 1,198.67 | 1,162.211 | 946.704 | 1,043.48 | 1,329.584 | 1,200.576 | 1,197.243 | 1,126.848 |
| Cost of Revenue
| 1,368.049 | 1,155.387 | 985.314 | 856.836 | 688.013 | 667.942 | 760.382 | 784.208 | 755.738 | 649.948 | 668.486 | 809.288 | 747.081 | 745.353 | 598.396 |
| Gross Profit
| 718.392 | 961.757 | 949.388 | 686.753 | 468.629 | 351.51 | 407.866 | 414.462 | 406.473 | 296.756 | 374.994 | 520.296 | 453.495 | 451.89 | 528.452 |
| Gross Profit Ratio
| 0.344 | 0.454 | 0.491 | 0.445 | 0.405 | 0.345 | 0.349 | 0.346 | 0.35 | 0.313 | 0.359 | 0.391 | 0.378 | 0.377 | 0.469 |
| Reseach & Development Expenses
| 242.696 | 244.789 | 252.674 | 215.729 | 195.461 | 161.537 | 149.319 | 146.403 | 131.871 | 130.022 | 126.477 | 136.315 | 130.486 | 100.8 | 105.674 |
| General & Administrative Expenses
| 104.627 | 109.313 | 95.227 | 92.408 | 76.446 | 80.325 | 95.792 | 83.791 | 77.628 | 63.262 | 61.875 | 71.504 | 67.912 | 56.623 | 39.605 |
| Selling & Marketing Expenses
| 129.176 | 162.468 | 144.667 | 109.696 | 75.614 | 78.756 | 84.62 | 86.138 | 97.459 | 80.122 | 87.908 | 86.566 | 86.546 | 88.814 | 85.216 |
| SG&A
| 194.887 | 271.781 | 239.894 | 202.104 | 152.06 | 159.081 | 180.412 | 169.929 | 175.087 | 143.384 | 149.783 | 158.07 | 154.458 | 145.437 | 124.821 |
| Other Expenses
| 28.34 | 73.878 | 12.178 | 347.814 | 5.031 | 218.738 | 39.753 | 1.523 | 244.964 | 28.579 | 27.267 | 11.494 | 17.917 | 11.857 | 9.217 |
| Operating Expenses
| 437.583 | 516.57 | 492.568 | 417.833 | 347.521 | 320.618 | 329.731 | 316.332 | 306.958 | 273.406 | 276.26 | 294.385 | 284.944 | 246.237 | 230.495 |
| Operating Income
| 280.809 | 574.672 | 519.279 | 655.054 | 154.36 | 30.892 | 78.135 | 98.13 | 99.515 | 23.35 | 98.734 | 225.911 | 168.551 | 205.653 | 297.957 |
| Operating Income Ratio
| 0.135 | 0.271 | 0.268 | 0.424 | 0.133 | 0.03 | 0.067 | 0.082 | 0.086 | 0.025 | 0.095 | 0.17 | 0.14 | 0.172 | 0.264 |
| Total Other Income Expenses Net
| 16.172 | 8.633 | -21.666 | -4.757 | -10.617 | 209.354 | 31.402 | -5.041 | 236.591 | 14.557 | 14.948 | -19.453 | 25.573 | 70.764 | -49.964 |
| Income Before Tax
| 296.981 | 583.305 | 497.613 | 650.297 | 143.743 | 240.246 | 109.537 | 93.089 | 336.106 | 37.907 | 113.682 | 206.458 | 194.124 | 276.417 | 247.993 |
| Income Before Tax Ratio
| 0.142 | 0.276 | 0.257 | 0.421 | 0.124 | 0.236 | 0.094 | 0.078 | 0.289 | 0.04 | 0.109 | 0.155 | 0.162 | 0.231 | 0.22 |
| Income Tax Expense
| 68.578 | 117.165 | 96.563 | 118.234 | 26.619 | 5.958 | 23.646 | 32.906 | 27.795 | 22.996 | 16.764 | 30.894 | 28.6 | 27.369 | 1.612 |
| Net Income
| 264.909 | 465.865 | 400.778 | 531.873 | 117.003 | 234.251 | 85.766 | 60.283 | 308.356 | 14.592 | 96.825 | 175.564 | 170.994 | 187.004 | 245.105 |
| Net Income Ratio
| 0.127 | 0.22 | 0.207 | 0.345 | 0.101 | 0.23 | 0.073 | 0.05 | 0.265 | 0.015 | 0.093 | 0.132 | 0.142 | 0.156 | 0.218 |
| EPS
| 3.42 | 6.01 | 5.17 | 6.86 | 1.51 | 3.02 | 1.11 | 0.78 | 3.98 | 0.19 | 1.25 | 2.32 | 2.2 | 2.62 | 3.62 |
| EPS Diluted
| 3.39 | 5.93 | 5.12 | 6.79 | 1.5 | 2.99 | 1.1 | 0.77 | 3.96 | 0.19 | 1.24 | 2.31 | 2.2 | 2.61 | 3.56 |
| EBITDA
| 473.814 | 743.721 | 651.272 | 786.208 | 284.002 | 385.789 | 252.014 | 214.364 | 447.311 | 148.421 | 209.266 | 285.963 | 265.807 | 264.848 | 390.969 |
| EBITDA Ratio
| 0.227 | 0.351 | 0.337 | 0.509 | 0.246 | 0.378 | 0.216 | 0.179 | 0.385 | 0.157 | 0.201 | 0.215 | 0.221 | 0.221 | 0.347 |